Close Menu

NEW YORK (GenomeWeb) – OpGen reported after the close of the market Tuesday that its fourth quarter revenues fell 23 percent year over year.

For the three months ended Dec. 31, 2018, OpGen logged $758,959 in revenues compared to $990,912 in the year-ago quarter.

Fourth quarter product sales fell 6 percent to $589,749 from $626,498; laboratory services revenue ticked up 34 percent to $12,510 from $935; and collaboration revenue dropped 57 percent to $156,700 from $363,479.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.